Researchers have been battling to find the cure for cancer since we began to understand what cancer really was. A cure is the ultimate goal, but most medical professionals and patients would be ecstatic even hearing about new treatments. Current cancer treatments often come rife with side effects so severe that many choose to forgo them altogether. Stopping the growth of malicious cancer cells is the main goal of treatment, and removing them altogether is even better. The problem is, this kind of treatment almost always causes damage to surrounding healthy cells.
A treatment that changes cancerous cells into healthy, supportive cells sounds ideal. Transforming malignant cells into antibodies that would attack remaining cancer cells sounds too good to be true. Thanks to a groundbreaking study by scientists at The Scripps Research Institute (TSRI), this new, powerful form of cancer therapy could really be on the horizon.
An Accidental Discovery
The laboratory team was working on therapies for certain immune cell or blood factor deficiencies when they noticed some unusual effects of antibodies on marrow cells. They had been searching for antibodies that activate growth-factor receptors on immature bone marrow cells, meaning the antibodies would be able to induce these cells to mature into specific blood cell types.
After successfully identifying a number of antibodies that activated the bone marrow cell-receptors this way, the researchers noticed that some of the antibodies were having unexpected effects on the cells. Some of them were maturing into cells that were radically different from what had been expected, such as neural cells. This got the team thinking, could this method be used to convert cancerous marrow cells (leukemia cells) into non-cancerous cells?
In the new study, Richard A. Lerner, institute professor and the Lita Annenberg Hazen professor of Immunochemistry at TSRI and senior investigator, teamed up with colleagues, including first author Kyungmoo Yea, an assistant professor of cellular and molecular biology at TSRI. They decided to test 20 of the recently discovered receptor-activating antibodies on acute myeloid leukemia cells taken from human patients. One of the antibodies ended up having an incredible impact on the leukemia cells.
Most acute myeloid leukemia cells have the thrombopoietin (TPO) receptor, a receptor the winning antibody selectively and potently activated in marrow cells. When the antibody was applied to healthy marrow cells, the cells matured into blood-platelet-producing cells (megakaryocytes). When applied to the acute myeloid leukemia cells, though, the antibody caused them to mature into dendritic cells, which are key support cells in the body’s immune system.
This alone would have been a success — the researchers had effectively transformed cancerous cells into non-cancerous, helpful immune system cells. The team pushed further, though, and found that with longer exposures to the antibodies and other regulated conditions, the dendritic cells matured even more. The final product was a group of cells that very closely resembled natural killer (NK) cells. One of the body’s rapid immune defenses, NK cells are capable of rapidly attacking potentially dangerous pathogens and tumors even if they don’t contain the biomarkers normally identified by other immune cells.
“That antibody could have turned those acute myeloid leukemia cells into a lot of other cell types, but somehow we were lucky enough to get NK cells,” Lerner said in a press release.
These induced NK cells possessed a few unique characteristics, observed by the team through electron microscopy. The cells possessed extending tendrils that had made their way through the outer membranes of closeby leukemia cells — the kind of cells they would still be, had they not been exposed to the antibody. In lab tests, the NK cells betrayed their former brethren at an impressive pace: a “modest” number of NK cells took out about 15 percent of the surrounding leukemic cell population in only 24 hours.
An interesting detail noted by the researchers is the purely fratricidal nature of the NK cells. They attacked only related leukemia cells, while unrelated breast cancer cells did not die off in large numbers when put into contact with the NK cells. The team is still unclear on why exactly the NK cells behave this way, but hypothesize that other, yet-to-be-discovered antibodies could be the key to turning other cancerous cell types into NK cells.
Lerner has named this type of therapy “fratricidins,” and pointed out that they would have several advantages. The antibodies would be clinically useful with little to no modification, and the high specificity of the NK cells would reduce the likelihood of damage to surrounding healthy cells. This would make fratricidins a possible treatment with much more tolerable effects than traditional treatments like chemotherapy.
On top of that, every cancer cell in a population is potentially convertible, so in a successful therapy the cancer-cell population might not just be reduced, but eliminated entirely.
The Latest on: Cancer Treatment Breakthrough
via Google News
The Latest on: Cancer Treatment Breakthrough
- Study offers new clues for treating brain cancer in childrenon November 25, 2020 at 10:20 am
Molecular details of 218 pediatric brain tumors reveals connections between certain proteins and a patient's prognosis.
- Breakthrough treatment for lung canceron November 24, 2020 at 5:38 am
Linda was diagnosed with stage 3A lung cancer. She had surgery followed by chemo but wasn’t sure what else could beat back the disease. Dr. Timothy Burns is an oncologist and a lung cancer researcher ...
- Experimental cancer vaccine passes animal tests, moves to human trialson November 23, 2020 at 7:38 pm
A novel cancer vaccine is moving to Phase 1 human trials in the United States after promising results from animal studies showed encouraging efficacy and a robust safety profile. A new study describes ...
- Greenwich LifeSciences Announces Second Publication and Second Poster Presentation of Phase III Clinical Trial of Potential Breakthrough Technology for Recurring Breast Canceron November 23, 2020 at 4:50 am
Greenwich LifeSciences Announces Second Publication and Poster Presentation of Phase III Clinical Trial of Breakthrough for Recurring Breast Cancer ...
- How science and money pushed longtime biotech to IPO and a potential breast cancer breakthroughon November 20, 2020 at 3:01 pm
This is it,' Olema CEO Sean Bohen said after he saw the company's experimental breast cancer drug. Apparently, the IPOs investors think so, too, making it one of the biggest new biotech offerings this ...
- Breakthrough technology boosts breast cancer diagnosison November 20, 2020 at 8:04 am
New technology which helps doctors more accurately diagnose breast cancer has been recognised by the US Food & Drugs Administration (FDA) for its exceptional potential clinical value.
- A new kind of artificial intelligence provides breakthrough in breast cancer diagnosison November 20, 2020 at 6:58 am
State-of-the-art technology which helps doctors more accurately diagnose breast cancer has been hailed as a breakthrough by the US Food & Drugs Administration (FDA) for its exceptional potential ...
- Revolutionary CRISPR-based genome editing system treatment destroys cancer cellson November 19, 2020 at 4:00 pm
Researchers have demonstrated that the CRISPR/Cas9 system is very effective in treating metastatic cancers, a significant step on the way to finding a cure for cancer. The researchers developed a ...
- Novel Approach Offers Hope to Children with Brain Canceron November 18, 2020 at 12:00 pm
Newcastle University research has revealed that experts can identify the time, nature, and outcome of medulloblastoma relapse from the biology of the disease at diagnosis and the initial therapy ...
- Breakthrough in childhood brain cancer will save liveson November 17, 2020 at 3:31 pm
A scientific breakthrough has enabled experts to predict relapse in a common childhood cancer and means doctors can tailor treatment for each individual child and improve prognosis.
via Bing News